Legend Biotech Announces Promising Phase 1 Results for LB2102 CAR-T Therapy in Lung Cancer Patients

Reuters
03 Jun
Legend Biotech Announces Promising Phase 1 Results for LB2102 CAR-T Therapy in Lung Cancer Patients

Legend Biotech Corporation has announced promising interim results from a Phase 1 study of LB2102, a DLL3-targeted CAR-T cell therapy, in patients with lung cancers. The study, presented at a recent conference, involved patients with relapsed or refractory small-cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) who had received at least one prior line of therapy. The results indicated that LB2102 was well tolerated, with no dose-limiting toxicities observed up to Dose Level 4. The study also showed encouraging signs of dose-dependent efficacy, with clinical responses correlating with CAR-T cell expansion. These findings support continued dose escalation and further clinical evaluation. Legend Biotech is conducting this study in the U.S. under an exclusive global license agreement with Novartis Pharma AG.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462529-en) on June 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10